 |
13 Diseases |  |
1 Trial |
|
1 Trial |  |
26 News |  |
- || CBP501 / CanBas, Opdivo (nivolumab) / Ono Pharma, BMS
P2 data, Journal, Metastases: A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ?3rd-line treatment of patients with advanced pancreatic adenocarcinoma. (Pubmed Central) - Mar 15, 2024
P2
The combination CBP(25)/(16)/CDDP/nivo demonstrated promising signs of efficacy and a manageable safety profile for the treatment of advanced PDAC.
- || CBP501 / CanBas
Trial completion: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 15, 2023
P2, N=36, Completed, Sponsor: CanBas Co. Ltd.
The combination CBP(25)/(16)/CDDP/nivo demonstrated promising signs of efficacy and a manageable safety profile for the treatment of advanced PDAC. Active, not recruiting --> Completed
- CBP501 / CanBas, Opdivo (nivolumab) / Ono Pharma, BMS
Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ? third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3 () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3110;
P2
SAE acute renal failure (arm 3, after 1 cycle) was assessed as possibly related to CBP501 and definitely related to cisplatin. Conclusions Preliminary results indicate clinically meaningful improvement and tolerable safety of CBP501, cisplatin and nivolumab as 3rd line treatment for metastatic PDAC.
- | CBP501 / CanBas
Trial completion date, Trial primary completion date: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jan 20, 2023
P2, N=36, Active, not recruiting, Sponsor: CanBas Co. Ltd.
Conclusions Preliminary results indicate clinically meaningful improvement and tolerable safety of CBP501, cisplatin and nivolumab as 3rd line treatment for metastatic PDAC. Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
- ||| CBP501 / CanBas
Enrollment closed, Enrollment change: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2022
P2, N=36, Active, not recruiting, Sponsor: CanBas Co. Ltd.
Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Mar 2023 Recruiting --> Active, not recruiting | N=92 --> 36
- ||| CBP501 / CanBas
Enrollment open: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 4, 2021
P2, N=92, Recruiting, Sponsor: CanBas Co. Ltd.
Recruiting --> Active, not recruiting | N=92 --> 36 Not yet recruiting --> Recruiting
- || CBP501 / CanBas
Trial completion date, Trial primary completion date: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 26, 2021
P2, N=92, Not yet recruiting, Sponsor: CanBas Co. Ltd.
Not yet recruiting --> Recruiting Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
- |||| CBP501 / CanBas
New P2 trial: Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 7, 2021
P2, N=92, Not yet recruiting, Sponsor: CanBas Co. Ltd.
- || CBP501 / CanBas
Trial completion: CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (clinicaltrials.gov) - Mar 10, 2021
P1b, N=47, Completed, Sponsor: CanBas Co. Ltd.
Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022 Active, not recruiting --> Completed
- || CBP501 / CanBas
Enrollment closed, Trial completion date, Trial primary completion date: CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (clinicaltrials.gov) - Jan 31, 2021
P1b, N=48, Active, not recruiting, Sponsor: CanBas Co. Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Apr 2021 | Trial primary completion date: Jan 2020 --> Mar 2021
- cisplatin / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts. (Poster Board 123) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1335;
P1b
The triple-drug combination is reasonably tolerable with preliminary signs of efficacy in refractory solid tumors, including those in which cisplatin and nivolumab have limited single-agent activity. Research Funding: CanBas Co., Ltd.
- | CBP501 / CanBas
Trial completion date, Trial primary completion date: CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (clinicaltrials.gov) - Jan 15, 2019
P1b, N=48, Recruiting, Sponsor: CanBas Co. Ltd.
Research Funding: CanBas Co., Ltd. Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Jan 2020
- | CBP501 / CanBas
Journal: CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding. (Pubmed Central) - Nov 2, 2017
Taken together, these results indicate that CBP501 inhibits binding of CaM with KRas and thereby suppresses the PI3K/AKT pathway, migration, invasion and EMT. These findings have identified a previously unrecognized effect of CBP501 on downstream KRas signaling mechanisms involving EMT and invasion, and provide support for the further clinical development of this agent.
- CBP501 / CanBas
Enrollment open: CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (clinicaltrials.gov) - Sep 7, 2017
P1b, N=42, Recruiting, Sponsor: CanBas Co. Ltd.
These findings have identified a previously unrecognized effect of CBP501 on downstream KRas signaling mechanisms involving EMT and invasion, and provide support for the further clinical development of this agent. Not yet recruiting --> Recruiting
- CBP501 / CanBas
Trial initiation date: CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (clinicaltrials.gov) - Jul 21, 2017
P1b, N=42, Not yet recruiting, Sponsor: CanBas Co. Ltd.
Not yet recruiting --> Recruiting Initiation date: May 2017 --> Aug 2017
- | CBP501 / CanBas
Journal: CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to Calmodulin binding. (Pubmed Central) - Jun 25, 2017
Taken together, these results indicate that CBP501 inhibits binding of CaM with KRas and thereby suppresses the PI3K/AKT pathway, migration, invasion and EMT. These findings have identified a previously unrecognized effect of CBP501 on downstream KRas signaling mechanisms involving EMT and invasion, and provide support for the further clinical development of this agent.
- | CBP501 / CanBas
New P1 trial: CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (clinicaltrials.gov) - Apr 13, 2017
P1b, N=42, Not yet recruiting, Sponsor: CanBas Co. Ltd.
- CBP501 / CanBas
Enrollment change, Metastases: Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Mar 14, 2017
P1, N=48, Completed, Sponsor: CanBas Co. Ltd.
These findings have identified a previously unrecognized effect of CBP501 on downstream KRas signaling mechanisms involving EMT and invasion, and provide support for the further clinical development of this agent. N=13 --> 48
- |||| CBP501 / CanBas
Trial completion, Metastases: Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 28, 2013
P2, N=201, Completed, Sponsor: CanBas Co. Ltd.
N=13 --> 48 Active, not recruiting --> Completed
- |||| CBP501 / CanBas
Trial completion, Metastases: Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) (clinicaltrials.gov) - Dec 18, 2012
P1/2, N=71, Completed, Sponsor: CanBas Co. Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | CBP501 / CanBas
Trial completion, Metastases: Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Oct 20, 2011
P1, N=13, Completed, Sponsor: CanBas Co. Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed